Alpelisib in PIK3CA-related overgrowth syndrome



Subscribe to be notified of changes or updates to this page.

1 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

The purpose of this study is to find out if alpelisib (BYL719; the “study drug”), is safe and effective (can help) people who have PIK3CA-related overgrowth spectrum (PROS) disease. 

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at CVAPResearch [at] or 267-426-0743.

Eligibility & Criteria

IRB #:
Official Title:
EPIK-P2: A Phase II double-blind study with an upfront, 16-week randomized, placebo-controlled period, to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS)
Study Phase:
Phase II
Eligible Age Range:
6 - 60 Years
Study Categories:

Visit Criteria

Participation will last for up to 5 years. Subjects will be assigned to take either the study drug or placebo for the first 16 weeks. From week 17 on, subjects will receive study drug. Study visits include the following assessments: blood draws, ECGs, Echocardiograms, tissue collection (if biopsy is performed as standard of care), whole body MRIs, x-rays, photographs of lesions, lung function tests, walk tests, completion of questionnaires and diaries, and some genetic testing (to confirm mutation status). Reimbursement for travel may be provided.